Literature DB >> 9653946

Analysis of cysteine and N-acetylcysteine in human plasma by high-performance liquid chromatography at the basal state and after oral administration of N-acetylcysteine.

D Tsikas1, J Sandmann, M Ikic, J Fauler, D O Stichtenoth, J C Frölich.   

Abstract

A high-performance liquid chromatographic method for the determination of free reduced cysteine and N-acetylcysteine in human plasma at the basal state and after oral administration of N-acetylcysteine is described. The method is based on acid-catalysed conversion of plasma thiols to the corresponding S-nitroso derivatives by excess of nitrite and their subsequent cation-pairing RP-HPLC with detection at 333 nm. Recovery rates of cysteine and N-acetylcysteine added to human plasma were 94.6 and 99.6%, respectively. Inter- and intra-day precision were below 6%. In healthy humans (n = 5), free reduced cysteine was determined to be (mean+/-S.E.) 10.0+/-0.96 microM. No N-acetylcysteine was detected in plasma of these subjects above the limit of detection (e.g. 170 nM). The method was successfully applied to a pharmacokinetic study on orally administered N-acetylcysteine to healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653946     DOI: 10.1016/s0378-4347(97)00670-1

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  14 in total

1.  Simultaneous determination of total homocysteine, cysteine, cysteinylglycine, and glutathione in human plasma by high-performance liquid chromatography: application to studies of oxidative stress.

Authors:  Thomas D Nolin; M Elizabeth McMenamin; Jonathan Himmelfarb
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-02-21       Impact factor: 3.205

Review 2.  Environmental toxicity, redox signaling and lung inflammation: the role of glutathione.

Authors:  Saibal K Biswas; Irfan Rahman
Journal:  Mol Aspects Med       Date:  2008-08-08

3.  In vivo contribution of amino acid sulfur to cartilage proteoglycan sulfation.

Authors:  Fabio Pecora; Benedetta Gualeni; Antonella Forlino; Andrea Superti-Furga; Ruggero Tenni; Giuseppe Cetta; Antonio Rossi
Journal:  Biochem J       Date:  2006-09-15       Impact factor: 3.857

4.  Antioxidants Promote Intestinal Tumor Progression in Mice.

Authors:  Zhiyuan V Zou; Kristell Le Gal; Ahmed E El Zowalaty; Lara E Pehlivanoglu; Viktor Garellick; Nadia Gul; Mohamed X Ibrahim; Per-Olof Bergh; Marcus Henricsson; Clotilde Wiel; Levent M Akyürek; Martin O Bergo; Volkan I Sayin; Per Lindahl
Journal:  Antioxidants (Basel)       Date:  2021-02-04

5.  Spectrophotometric determination of N-acetyl-L-cysteine and N-(2-mercaptopropionyl)-glycine in pharmaceutical preparations.

Authors:  Lea Kukoc-Modun; Njegomir Radić
Journal:  Int J Anal Chem       Date:  2011-05-23       Impact factor: 1.885

6.  N-acetylcysteine supplementation controls total antioxidant capacity, creatine kinase, lactate, and tumor necrotic factor-alpha against oxidative stress induced by graded exercise in sedentary men.

Authors:  Donrawee Leelarungrayub; Raphiphat Khansuwan; Prapas Pothongsunun; Jakkrit Klaphajone
Journal:  Oxid Med Cell Longev       Date:  2011-08-23       Impact factor: 6.543

Review 7.  N-acetylcysteine in COPD: why, how, and when?

Authors:  Claudio M Sanguinetti
Journal:  Multidiscip Respir Med       Date:  2016-02-03

8.  Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.

Authors:  Mario Cazzola; Luigino Calzetta; Francesco Facciolo; Paola Rogliani; Maria Gabriella Matera
Journal:  Respir Res       Date:  2017-01-24

Review 9.  Role of N-acetylcysteine in the management of COPD.

Authors:  Anna M Sadowska; J Verbraecken; K Darquennes; W A De Backer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

10.  Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials.

Authors:  Zikai Sun; Qiang Fu; Longxing Cao; Wen Jin; Lingling Cheng; Zhiliang Li
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.